Hansa Biopharma bolsters leadership team with new executive appointments
Ella Day | July 31, 2025 | Appointment | Research and Development | Chief Human Resources Officer, Chief Legal Officer, Corporate, Executive Leadership Team, Hansa Biopharma, Vice President Corporate Affairs
Hansa Biopharma has announced three senior leadership appointments to support its global expansion as well as pre-commercial activities in the US ahead of two upcoming phase 3 trials and a potential Biologics License Application submission.
Brian Gorman will join as chief legal officer and corporate secretary on 4 August. With over 20 years of experience, Gorman has previously held senior roles at Sinclair Pharma, Calliditas Therapeutics and Opiant Pharmaceuticals. He began his career at Cleary Gottlieb Steen & Hamilton and brings deep expertise in corporate governance and strategic transactions.
Sandra Frithiof, also joining on this date, will become chief human resources officer. She brings more than 25 years of HR leadership experience across healthcare, legal and mobility sectors. This includes roles at Calliditas Therapeutics and Karolinska University Hospital, Sweden.
On 1 September, Kerstin Falck Lagercrantz will take up the role of vice president corporate affairs. She joins from Pfizer, where she led corporate affairs through health policy negotiations during the COVID-19 pandemic. She will report to Maria Törnsén, chief operating officer and US president.
“These appointments bring a wealth of expertise to our leadership team at a crucial time in our growth journey,” said Renée Aguiar-Lucander, CEO of Hansa Biopharma. “Brian, Sandra and Kerstin will play vital roles as we advance our mission to deliver transformative treatments for patients with rare immunological diseases.”
Ella Day
31/7/25
Related Content
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating …
